Pratima Cherukuri, chief scientific officer at Genezen answers some of most pressing questions about developments in biologics processing.
Q: Bioprocessing at commercial scale is becoming industrial in scope. Given your offerings and capabilities, what protein/gene expression or chemistry platforms are offering developers and sponsors better yields, efficiencies, and programme success?
A: Producer cell lines offer an attractive alternative to transient transfection when it comes to larger-scale manufacturing. They reduce or eliminate the need for plasmid transfection, which decreases process complexity and the risk of batch-to-batch variation or human error. Producer cell lines also use less expensive raw materials and labour as compared with transient transfection, resulting in lower associated costs.